摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-3-butoxypropane-1,2-diol

中文名称
——
中文别名
——
英文名称
(S)-3-butoxypropane-1,2-diol
英文别名
(2S)-3-butoxypropane-1,2-diol
(S)-3-butoxypropane-1,2-diol化学式
CAS
——
化学式
C7H16O3
mdl
——
分子量
148.202
InChiKey
JCYHHICXJAGYEL-ZETCQYMHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0
  • 重原子数:
    10
  • 可旋转键数:
    6
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    49.7
  • 氢给体数:
    2
  • 氢受体数:
    3

文献信息

  • Isomigrastatin Analogs In The Treatment Of Cancer
    申请人:Danishefsky Samuel J.
    公开号:US20090054488A1
    公开(公告)日:2009-02-26
    The present invention provides compounds having formula (I): (I) wherein n, R 1 -R 5 , R a -R b , Q, Y 1 and Y 2 are as defined herein; and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis.
    本发明提供具有以下式(I)的化合物:(I)其中n,R1-R5,Ra-Rb,Q,Y1和Y2如本文所定义;此外还提供了其合成方法、组合物以及在治疗包括癌症、转移和涉及增加血管生成的各种疾病中使用的方法。
  • SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
    申请人:JAPAN TOBACCO INC.
    公开号:US20140221378A1
    公开(公告)日:2014-08-07
    Provided is a substituted spiropyrido[1,2-a]pyrazine derivative or a pharmaceutically acceptable salt thereof, which is useful as an anti-HIV agent. The present invention relates to a compound represented by the following formula [I] or [II] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.
    提供了一种替代的螺环吡啶并[1,2-a]吡嗪衍生物或其药用盐,其作为一种抗HIV药物。本发明涉及以下式[I]或[II]所表示的化合物或其药用盐: 其中每个符号如规范中定义的那样。
  • Migrastatin analogs and uses thereof
    申请人:Huang Xin-Yun
    公开号:US20070037783A1
    公开(公告)日:2007-02-15
    In one aspect, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of general formula (I), wherein R 1 —R 6 , R a—R C , Q, Y 1 , Y 2 and n are as defined herein, whereby the composition is formulated for administration to a subject at a dosage between about 0.1 mg/kg to about 50 mg/kg of body weight. In another aspect, the present invention provides a method for treating breast tumor metastasis in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the inventive composition described directly above and a pharmaceutically acceptable carrier, adjuvant or vehicle.
    在一个方面,本发明提供了制剂,包括通式(I)中化合物的治疗有效量,其中R1-R6,Ra-RC,Q,Y1,Y2和n的定义如本文所述,该制剂被制成适用于给予受试者剂量在0.1毫克/千克到50毫克/千克的体重之间。在另一个方面,本发明提供了一种治疗乳腺肿瘤转移的方法,包括向需要治疗的受试者直接上述描述的创新制剂和药学上可接受的载体、佐剂或载体的治疗有效量的给药。
  • MIGRASTATIN ANALOGS AND USES THEREOF
    申请人:SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    公开号:US20140011844A1
    公开(公告)日:2014-01-09
    The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis, wherein R 1 -R 6 , R a -R c , Q, Y 1 , Y 2 and n are as defined herein.
    本发明提供具有式(I)的化合物,并且还提供了其合成方法、组合物以及在治疗包括癌症、转移和涉及增加血管生成的各种疾病中使用的方法,其中R1-R6、Ra-Rc、Q、Y1、Y2和n如本文所定义。
  • NOVEL COMPOUNDS HAVING ANTIVIRAL ACTIVITY
    申请人:NISSIN FOOD PRODUCTS CO., LTD.
    公开号:EP0957107B1
    公开(公告)日:2004-07-21
查看更多